10 analysts rate Syndax Pharmaceuticals (NASDAQ:SNDX) as "Moderate Buy" with an average price target of $35.33; TD SYNNEX (SNX)
Syndax Pharmaceuticals (NASDAQ:SNDX) holds a "Moderate Buy" rating from ten analysts, with an average price target of $35.33. The company, focusing on cancer therapies, has seen significant institutional investment increases. Meanwhile, TD SYNNEX (SNX) updated its Q4 earnings guidance, projecting EPS of $2.80 to $3.30, with revenue estimates between $14.9 billion and $15.7 billion. The company reported Q3 earnings of $178.6 million, exceeding expectations.
September 26, 2024
11 Articles